Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Sep 14;316(9):622.
doi: 10.1007/s00403-024-03361-x.

Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management

Deesha D Desai #  1   2 , Ambika Nohria #  3 , Michelle Sikora  3   4 , Nnaemeka Anyanwu  3 , Jerry Shapiro  3 , Kristen I Lo Sicco  3
Affiliations
Comparative Study

Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management

Deesha D Desai et al. Arch Dermatol Res. .

Abstract

LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compare the efficacy and safety of LDOM in combination with spironolactone versus LDOM with finasteride or dutasteride in women with AGA. Our analysis revealed that both combination therapies produced similar improvements in hair growth and had comparable safety profiles. Although the LDOM with finasteride/dutasteride group showed a greater average increase in hair width and density, these differences were not statistically significant. These results endorse the use of LDOM in combination with either spironolactone or finasteride/dutasteride for female AGA, and underscore the necessity for further research to validate these findings and assess long-term treatment outcomes.

Keywords: Alopecia; Dutasteride; Finasteride; Hair loss; Minoxidil; Spironolactone.

PubMed Disclaimer

References

    1. Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152(3):466–473 - DOI - PubMed
    1. Rathnayake D, Sinclair R (2010) Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 28(3):611–618 - DOI - PubMed
    1. Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S (2018) A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol 32(12):2257–2263 - DOI - PubMed
    1. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A et al (2021) Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol 84(6):1644–1651 - DOI - PubMed

Publication types

LinkOut - more resources